307 related articles for article (PubMed ID: 26530882)
1. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
2. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
3. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
4. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and biological features of familial nonmedullary thyroid carcinoma].
Gao J; Yu Y; Li X; Zhao J; Zhao C; Zhao J; Liu Y; Li Y; Gao M
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):202-6. PubMed ID: 24785281
[TBL] [Abstract][Full Text] [Related]
7. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
8. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
9. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
[TBL] [Abstract][Full Text] [Related]
10. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Zhang T; Xing M
J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
[TBL] [Abstract][Full Text] [Related]
11.
Orois A; Gara SK; Mora M; Halperin I; Martínez S; Alfayate R; Kebebew E; Oriola J
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31703244
[TBL] [Abstract][Full Text] [Related]
12. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
13. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
15. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
16. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
[TBL] [Abstract][Full Text] [Related]
17. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
18. Is Familial Nonmedullary Thyroid Cancer A More Aggressive Type of Thyroid Cancer?
Muallem Kalmovich L; Jabarin B; Koren S; Or K; Marcus E; Tkacheva I; Benbassat C; Steinschneider M
Laryngoscope; 2021 Feb; 131(2):E677-E681. PubMed ID: 32761812
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features of familial nonmedullary thyroid carcinoma.
Fan YF; Zhang B; Yang X; Shang ZH; Liu HF; Xie Y; Liu YW; Gao WS; Wu Q; Li XY
Chin Med J (Engl); 2015 Apr; 128(8):1037-41. PubMed ID: 25881596
[TBL] [Abstract][Full Text] [Related]
20. Comparison Between Clinicopathological Characteristics,
Yang T; Huang L; Chen C; Luo H; Jiang Y
Front Oncol; 2021; 11():616974. PubMed ID: 34926235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]